drugset / Trial / NCT05934110
Study Exploring the Supportive Effect of Acarbose in Weight Management
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination product with modified release (MR) orlistat, orlistat in its conventional dosage form and placebo.
Timeline
- Start
- 2023-04-18
- Primary completion
- 2023-11-21
- Completion
- 2024-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acarbose | Unknown | 20 mg | Oral |
| Subject | Acarbose | Unknown | 40 mg | Oral |
| Subject | Orlistat | Small molecule | 60 mg | Oral |
| Subject | Orlistat | Small molecule | 120 mg | Oral |